Why the study?
Current transcatheter pulmonary valve replacement only treats patients weighing at least 20 kg, leaving smaller children unable to receive timely valve replacement and at risk for right ventricular dilation.
Does the IRIS Valve demonstrate feasibility, structural integrity, and favorable tissue response in a preclinical porcine model?
Does the IRIS Valve demonstrate feasibility, structural integrity, and favorable tissue response in a preclinical porcine model?
Answers are grounded in this paper and cite their sources.
A novel growth-accommodating transcatheter pulmonary valve (IRIS Valve) showed promising preclinical feasibility and safety, potentially enabling earlier transcatheter valve replacement in small children (8-10 kg) with congenital heart defects.
BACKGROUND: Congenital heart defects affect approximately 1% of births in the United States and Europe, with >1 million children in the United States living with congenital heart defects. Many experience abnormalities in the right ventricular outflow tract, often necessitating surgical intervention early in life. However, the initial repairs typically are temporary solutions as many patients will eventually need pulmonary valve replacement to address pulmonary valve regurgitation and prevent right ventricle failure. Addressing progressive pulmonary valve regurgitation, ideally in patients weighing 8 to 10 kg, is critical to prevent right ventricle dysfunction. Transcatheter pulmonary valve replacement currently treats patients weighing at least 20 kg. Unfortunately, smaller children must wait for valve replacement and risk right ventricular dilation. METHODS: To address this challenge, we have developed the IRIS Valve, a growth-accommodating transcatheter pulmonary heart valve inspired by origami targeting implantation in at least 8 kg children. The valve stent underwent finite element analysis with validation by fracture testing. Using a 12-Fr transcatheter system, the IRIS valve was implanted into 8 to 17 kg Yucatan mini pigs for 6 months. RESULTS: Benchtop fracture testing and finite element analysis confirmed the stent's ability to be crimped to a 3-mm diameter for loading into a 12-Fr transcatheter system and expanded to 20 mm without fracture. Animal studies successfully demonstrated excellent integration within the pulmonary valve annulus, intact valve integrity, and favorable tissue response. CONCLUSIONS: The IRIS Valve offers a promising solution for earlier treatment of heart valve disease in pediatric patients with congenital heart defects, potentially improving outcomes in this vulnerable population.
No takes yet. Share an insight, caveat, or question.
Agwu et al. (2025) studied Congenital heart defects / Pulmonary valve regurgitation. IRIS Valve was evaluated on Stent fracture, integration, valve integrity, and tissue response.
Synapse has enriched 10 related papers. Consider them for comparative context: